 Enveric Biosciences NASDAQ:ENVB announced that it has filed its tenth Patent Cooperation Treaty PCT application directed to tryptamine-based derivative molecule, completing the companys broad series of PCT applications covering this family of compounds. The Naples-based biotech companys robust tryptamine-derivative intellectual property portfolio claims novel molecules structurally related to certain naturally occurring psychedelics, such as dimethyltryptamine DMT, psilocybin, psilocin, and 5-MeO-DMT. 